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Although much emphasis has been placed on screening for
albuminuria in type II diabetic patients, less attention has
been focused on the role of glomerular filtration rate (GFR) in
the assessment of risk. Herein, we examined the association
between GFR and vascular complications in a consecutive
cohort of 5174 type II diabetic patients between 1995 and
2000. Renal function was assessed by GFR (estimated by
Modification of Diet in Renal Disease equation). The
frequency of chronic kidney disease (CKD) as defined by GFR
o60 ml/min/1.73m2, micro- and macrovascular
complications, and their associations were analyzed. In this
study cohort, 6% had serum creatinine X150 lmol/l and
15.8% had CKD. After adjustment for potential confounders,
including urinary albumin excretion, odds ratios [95%
confidence interval (CI)] across different stages of estimated
GFR (X90, 60–89, 30–59, 15–29, o15 ml/min/1.73 m2) for
macrovascular disease were 1.00, 1.42 [1.12–1.80], 1.80
[1.32–2.45], 2.74 [1.64–4.56], and 4.05 [1.77–9.26], respectively
(P for trend o0.001); for retinopathy were 1.00, 1.23
[1.04–1.46], 1.80 [1.40–2.30], 2.05 [1.25–3.37], and 4.12
[1.56–10.90], respectively (P for trend o0.001); for sensory
neuropathy were 1.00, 1.53[1.27–1.85], 2.09 [1.58–2.76], 4.32
[2.41–7.77], and 3.16 [1.25–8.02], respectively (P for trend
o0.001); and for microalbumuria (with GFR o15 ml/min/
1.73 m2 excluded from the analysis) were 1.00, 1.51
[1.30–1.75], 5.80 [4.52–7.44], and 52.5 [16.4–168.2]
respectively (P for trend o0.001). Measurement of serum
creatinine alone without GFR may underestimate renal
impairment in type II diabetic patients. Decreasing GFR
was significantly associated with increasing frequency of
micro- and macrovascular complications.
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The prevalence of diabetic nephropathy is particularly high in
Asian type II diabetes patients, including those in Hong
Kong.1,2 Albuminuria is a well-known predictor of cardio-
vascular mortality.3,4 Albuminuria may be the renal expres-
sion of general vascular endothelial damage, and thus an
indicator of atherosclerosis.5 There is also emerging evidence
showing that chronic kidney disease (CKD) is an indepen-
dent risk factor for cardiovascular disease.6–8 In the United
States, a higher prevalence of decreased glomerular filtration
rate (GFR) (o60 ml/min/1.73 m2) has been shown among
adults with diabetes mellitus compared with adults without
diabetes mellitus (13 versus 7%).9 However, there is a paucity
of data investigating the relationship between GFR and
vascular complications in type II diabetes patients. In this
cohort, we examined the association between GFR and
macro- and microvascular complications in Chinese patients
with type II diabetes.
RESULTS
In this cohort of 5174 patients with type II diabetes, 6% had
serum creatinineX150 mmol/l; when this level was used as an
index of reduced renal function. By contrast, 15.8% of
patients had CKD defined by estimated GFR o60 ml/min/
1.73 m2 (stage 3 or higher) and 37.5% of patients had mild
reduction in estimated GFR (60–89 ml/min/1.73 m2). Table 1
compares the clinical and metabolic parameters of patients
according to the stages of estimated GFR as defined by the
National Kidney Foundation Kidney Disease Outcomes
Quality Initiative clinical guidelines.6 Except for patients
with end-stage renal disease (defined as GFRo15 ml/min/
1.73 m2), patients with lower GFR were generally older, had
longer duration of diabetes, had higher systolic blood
pressure, total cholesterol, low-density lipoprotein (LDL-C),
and triglycerides (TG), but lower high-density lipoprotein
(HDL-C) levels, and higher urinary albumin excretion (UAE)
compared to those with normal GFR. There was a trend for
body mass index (BMI) to decrease with decreasing GFR, and
the lowest waist circumference was observed in female type II
diabetes patients with the lowest GFR.
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Figure 1 shows the frequency of diabetic complications
among subjects with different stages of estimated GFR at
baseline. In this cohort, the frequencies of macrovascular
disease, retinopathy, neuropathy and albuminuria (micro- or
macroalbuminuria) were 14.1, 26.2, 30.7, and 42.7%,
respectively. Lower estimated GFR was associated with
increased frequencies of macrovascular disease, retinopathy,
sensory neuropathy, and albuminuria.
Reduction in estimated GFR was associated with a
progressively higher risk of micro- and macrovascular
complications of diabetes after adjusting for age and sex.
The associations between estimated GFR and diabetic
complications remained significant after further adjustment
for smoking, family history, blood pressure, HDL-C, LDL-C,
TG, hemoglobin A1c, fasting plasma glucose (FPG), and UAE
(Table 2). For macrovascular complications, odds ratios
(ORs) across different stages of estimated GFR were 1.00,
1.42 (1.12–1.80), 1.80 (1.32–2.45), 2.74 (1.64–4.56), and 4.05
(1.77–9.26) (P for trend o0.001). The ORs for different
stages of estimated GFR with retinopathy were 1.00, 1.23
(1.04–1.46), 1.80 (1.40–2.30), 2.05 (1.25–3.37), and 4.12
(1.56–10.9) (P for trend o0.001). Subjects with estimated
GFR less than 15 ml/min/1.73 m2 were excluded in the
analysis for albuminuria. The ORs for different stages of
estimated GFR were 1.00, 1.51 (1.30–1.75), 5.80 (4.52–7.44),
and 52.5 (16.4–168.2) (P for trend o0.001) after adjusting
for covariates. For sensory neuropathy, increasing stages of
GFR were associated with 1.00-, 1.53-, 2.09-, 4.32-, and 3.16-
fold increases in multivariate-adjusted ORs (P for trend
o0.001).
DISCUSSION
In this study involving more than 5000 type II diabetes
patients, 15.8% had evidence of CKD, defined as estimated
GFR less than 60 ml/min/1.73 m2 (stage 3 or higher). Another
37.5% of patients had stage 2 CKD, defined as GFR between
60 and 89 ml/min/1.73 m2, resulting in a total of more than
50% with mild to moderate renal impairment. These findings
were in accordance with reports showing that Asian type II
diabetes patients probably have one of the highest prevalence
rates of diabetic nephropathy (about 20% macroalbuminuria
and 40% microalbuminuria) in the world.1,2 We calculated
GFR from serum creatinine based on the modified equation
Table 1 | Clinical and metabolic characteristics of 5174 Chinese type II diabetes patients according to categories of estimated
GFR
Stages of glomerular filtration rate
1 2 3 4 5
Estimated GFR (ml/min/1.73 m2) X90 60–89 30–59 15–29 o15 Pa
Number of patients 2420 1938 640 133 43
Female (%) 58.9 51.5 57.0 63.2 76.7 o0.001
Age (years) 52.1712.3 63.3711.4 70.279.6 70.179.1 65.8713.0 o0.001
Duration of diabetes (years) 5.775.6 7.776.4 11.477.9 12.976.8 10.976.2 o0.001
Body mass index (kg/m2) 25.174.3 25.073.7 24.973.7 25.073.5 24.273.5 o0.001
Waist (cm)
Female 82.3710.2 84.179.6 85.179.6 85.778.9 81.679.8 o0.001
Male 87.5710.4 88.679.1 89.079.0 86.479.4 88.676.1 0.002
Systolic BP (mmHg) 130719 138720 147723 155727 154727 o0.001
Diastolic BP (mmHg) 77711 77711 77713 77712 76715 0.961
HbA1c (%) 7.7171.87 7.8071.83 7.9771.87 7.7671.83 7.2271.51 0.023
Fasting plasma glucose (mmol/l) 8.7773.20 8.9073.46 8.9973.86 8.6273.89 7.7373.16 0.060
Total cholesterol (mmol/l) 5.2871.14 5.4171.14 5.6271.33 5.6671.49 5.6971.51 o0.001
HDL-C (mmol/l) 1.2970.36 1.2670.35 1.1870.36 1.1870.36 1.1270.27 o0.001
LDL-C (mmol/l) 3.2770.92 3.4070.96 3.5171.10 3.4871.24 3.4771.00 0.039
Triglycerides (mmol/l) 1.24 (0.87–1.87) 1.38 (0.97–2.07) 1.71 (1.18–2.53) 1.82 (1.21–2.54) 1.75 (1.39–2.43) o0.001
Serum creatinine (mmol/l) 61 (55–72) 84 (72–93) 123 (102–142) 225 (197–256) 401 (342–471) o0.001
Urinary albumin excretion (mg/24 h) 14 (8–40) 21 (9–84) 167 (36–879) 1488 (272–3049) 2804 (1560–3441) o0.001
Current or ex-smokers (%) 25.3 30.7 33.2 28.0 27.9 o0.001
BP, blood pressure; GFR, glomerular filtration rate; HDL-C, high-density lipoprotein; LDL-C, low-density lipoprotein.
aParameters were age- and sex-adjusted, except for age, sex and smoking.
All values are expressed as mean7s.d. or median (interquartile range).
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Figure 1 | Frequency of microvascular (retinopathy, neuropathy
and albuminuria) and macrovascular complications among 5174
Chinese type II diabetes patients according to categories of
estimated GFR (P for trend o0.001).
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from the Modification of Diet in Renal Disease (MDRD)
study (Greene T et al. J Am Soc Nephrol 2000; 11: A0828
(Abstract)).10 It has been shown that the MDRD equation
underestimated GFR by 6.2% in patients with CKD in the
States.11 A recent report has shown that the MDRD equation
is accurate in diagnosing and stratifying CKD in a small
cohort of 50 type I and 110 type II diabetes patients.12
However, contrary to the results of Rigalleau et al.,13 Ibrahim
et al.13 found that MDRD substantially underestimated GFR
in 1286 type I diabetes patients with normal serum creatinine
from the Diabetes Control and Complications Trial when
compared to GFR measured by iothalamate excretion, the
latter being regarded as the gold standard for GFR
measurement. Creatinine clearance showed a worse correla-
tion with insulin clearance than did the MDRD formula,
particularly at lower levels of GFR where creatinine secretion
tended to grossly overestimate GFR.6,14 The lack of validation
of estimated GFR in type II diabetic populations, especially
those with renal impairment, together with the absence of
calibration of serum creatinine to the MDRD laboratory
should call for further research in these aspects. Although the
MDRD equation had yet to be validated in the Chinese type
II diabetic population, we were able to show a marked
increase in the frequency of CKD when the estimated GFR
(15.8%) rather than the serum creatinine (6%) was used. Our
findings therefore lend support to the proposition that
estimated GFR should be reported along with serum
creatinine level to alert physicians to the presence of CKD.
Furthermore, our findings have shown a significant associa-
tion between GFR and both macro- and microvascular
complications in type II diabetes. This was independent of
albuminuria and all other potential confounding factors.
Albuminuria, a marker for both vascular and renal disease, is
now recognized as a risk factor for atherosclerosis and
cardiovascular events.3–5 It may precede the onset of diabetes
and/or hypertension and is closely associated with obesity and
dyslipidemia.15 Our findings suggested that, other than
albuminuria, lower GFR per se was associated with both macro-
and microvascular complications. It is plausible that with the
onset of CKD, there are further changes in the metabolic milieu,
notably increases in circulating cytokines leading to a chronic
inflammatory state, often being made worse by sepsis and
malnutrition in these subjects.16 Besides, anemia and metabolic
bone disease, which often accompany CKD, can also adversely
affect cardiac and vascular function.17 In short, although the
increased cardiovascular risk in patients with CKD is now
increasingly recognized,18 our findings suggested that CKD in
type II diabetes patients was also associated with increased
macro- and microvascular complications.
In addition to the close inter-relationships between
inflammatory markers (including interleukin-6 and tumor
necrosis factor-a), insulin resistance, and diabetes mellitus,19
our group has previously reported associations between
increased white cell count and diabetic microvascular
complications in type II diabetes patients.20 Taken together,
inflammation may play a linking role for the associations
between type II diabetes, vascular complications, and CKD.
Prospective and experimental studies are required to clarify
the nature of these associations.
Paradoxically, in our study cohort, those with GFR
o15 ml/min/1.73 m2 were younger and had lower BMI and
waist circumference (in female patients only) than those with
GFR between 15 and 59 ml/min/1.73 m2. Diabetic nephro-
pathy is known to have genetic predispositions,21 and this
Table 2 | ORs from logistic regression analysis for diabetic complications of macrovascular disease, retinopathy, albuminuria
and neuropathy according to categories of estimated GFR among 5174 Chinese patients with type II diabetes
Stages of glomerular filtration rate
1 2 3 4 5 P
Median estimated GFR (ml/min/1.73 m2) 107 78 49 23 12
Macrovascular disease
Age-adjusted OR 1.00 2.06 (1.70–2.49) 5.95 (4.68–7.56) 13.1 (8.95–19.30) 12.0 (6.36–22.7) o0.001
Multivariate-adjusted ORa 1.00 1.42 (1.12––1.80) 1.80 (1.32–2.45) 2.74 (1.64–4.56) 4.05 (1.77–9.26) o0.001
Retinopathy
Age-adjusted OR 1.00 1.74 (1.50–2.02) 5.41 (4.42–6.62) 12.81 (8.65–19.0) 16.82 (8.15–34.7) o0.001
Multivariate-adjusted ORa 1.00 1.23 (1.04–1.46) 1.80 (1.40–2.30) 2.05 (1.25–3.37) 4.12 (1.56–10.9) o0.001
Neuropathy
Age-adjusted OR 1.00 1.95 (1.64–2.30) 4.99 (3.98–6.26) 15.11 (9.44–21.2) 7.55 (3.85–14.8) o0.001
Multivariate-adjusted ORa 1.00 1.53 (1.27–1.85) 2.09 (1.58–2.76) 4.32 (2.41–7.77) 3.16 (1.25–8.02) o0.001
Albuminuriab
Age-adjusted OR 1.00 1.74 (1.52–1.99) 9.31 (7.47–11.6) 65.1 (26.4–160.2) o0.001
Multivariate-adjusted ORc 1.00 1.51 (1.30–1.75) 5.80 (4.52–7.44) 52.5 (16.4–168.2) o0.001
GFR, glomerular filtration rate; OR, odds ratio.
aFinal model was adjusted for age, sex, smoking, duration of diabetes, family history of diabetes, waist circumference, blood pressure, body mass index, HbA1c, FPG, HDL-C,
LDL-C, TG and UAE rate.
bIndividuals with GFRo15 ml/min/1.73 m2 were excluded.
cFinal model was adjusted for all the above variables except UAE rate.
Kidney International (2006) 69, 383–387 385
APS Kong et al.: Glomerular filtration rate and managing type II diabetes o r i g i n a l a r t i c l e
might account for the younger age in our cohort with end-
stage renal disease. The reverse epidemiology of lower
adiposity in renal impaired patients may be explained by
the catabolic state of end-stage renal disease.22,23 Reduced
clearance of metabolic waste products and inflammatory
cytokines can lead to vascular inflammation, which is further
aggravated by increased malnutrition, catabolism, and
proneness to sepsis in patients with end-stage renal disease.
Other studies have demonstrated the association of low BMI
with all-cause mortality and cardiovascular end points in
subjects with or without diabetes.24,25
There were several limitations in this study. First, it was
hospital based. Selection bias was a potential confounding
variable. However, the lack of a comprehensive health
insurance policy and primary health care system in Hong
Kong implied that the majority of patients, especially those
with chronic diseases like diabetes, were usually managed in
public hospitals. Second, the cross-sectional design precluded
the assignation of a causal relationship between CKD and
vascular complications. Third, GFR was estimated from
serum creatinine rather than measurements from renal
clearance of iothalamate, a method that was impractical to
carry out in a large-scale study and was not readily available
in most clinical settings. Of note, the natural history of
diabetic nephropathy was characterized by the initial
hyperfiltration phase, represented by high values of GFR,
which could be double that of normal value, and was
followed by a gradual decline of GFR.21 The result of our
study did not preclude the importance of measuring urinary
albumin but highlighted the stark need to measure both GFR
and urinary albumin levels during the management of type II
diabetes patients.
In conclusion, both CKD and albuminuria were common
among Chinese patients with type II diabetes. While
decreasing GFR was significantly and independently asso-
ciated with macro- and microvascular complications in our
study cohort, the nature of these associations requires further
elucidation.
MATERIALS AND METHODS
Patients and methods
The Prince of Wales Hospital (the teaching hospital of the Chinese
University of Hong Kong) serves a population of over 1.2 million.
The Diabetes Center registers 30–50 patients referred from the
community and hospital clinics or discharged from the hospital
weekly. Since 1995, as part of a continuous quality improvement
program, all newly referred patients have undergone a comprehen-
sive assessment of complications and risk factors based on the
European DIABCARE protocol26 to form the Hong Kong Diabetes
Registry. Between 1995 and 2000, a consecutive cohort of 5426 type
2 diabetes patients was assessed. After excluding subjects with type 1
diabetes (n¼ 252), 5174 patients with type II diabetes were included
in the analysis. Informed consent was obtained at the time of
assessment. The study was approved by The Chinese University of
Hong Kong Clinical Research Ethics Committee.
Clinical assessments included measurement of BMI, waist to hip
ratio with subjects wearing light clothing and no shoes; sitting blood
pressure after at least 5 minutes of resting, visual acuity, fundoscopy
through dilated pupils and foot examination using a monofilament
and graduated tuning fork. Peripheral vascular disease was defined
by the absence of foot pulses on palpation, and confirmed by
Doppler ultrasound examination showing the ankle:brachial ratio to
be less than 0.9. Fundi were examined by either physicians trained in
diabetes and endocrinology or ophthalmologists. Retinopathy was
defined as the presence of dot and blot hemorrhages, hard exudates,
cotton wool spots, neovascularization, laser scars, or a history of
vitrectomy. Sensory neuropathy was diagnosed if two of the
following findings were present: reduced sensation to monofilament
examination in any part of the sole with normal skin, a score ofp6/
8 (age less than 65 years) or p4/8 (age greater than 65 years) using
the graduated tuning fork, or typical symptoms of numbness or
abnormal sensation over both lower limbs. Macrovascular compli-
cations were defined as peripheral vascular disease (defined as
above), history of stroke, myocardial infarction, angina, and heart
failure requiring hospitalization and revascularization procedures. A
total of 252 patients with type I presentation, defined as acute
presentation with diabetic ketoacidosis, heavy ketonuria (43þ ), or
continuous requirement of insulin within 1 year of diagnosis27 were
excluded from analysis.
Fasting blood samples were taken for measurement of FPG,
lipids including total cholesterol, HDL-C, TG, and calculated LDL-
C, renal and liver functions. Samples for complete blood count and
glycosylated hemoglobin A1c were collected in ethylenediaminete-
traacetic acid tubes. A random spot urine sample and a timed
urinary collection (4 or 24 h) were obtained to define albuminuric
status after exclusion of urinary tract infection, using mid-stream
urine for culture and microscopy. Normoalbuminuria was defined
as UAE o30 mg/day and spot urine albumin:creatine ratio
o3.5 mg/mmol. Albuminuria was defined as either UAE X30 mg/
day or albumin:creatine ratio X3.5 mg/mmol.28 Estimated GFR
(expressed in 6 ml/min/1.73 m2) was calculated using the modified
MDRD formula.10,11
GFR ¼ 186½SCR0:0111:154½age0:203½0:742 if female
where SCR was serum creatinine expressed as mmol/l.
Laboratory assays
Plasma glucose was measured by a hexokinase method (Hitachi 911
automated analyser, Boerhringer Mannheim, Mannheim, Germany).
Hemoglobin A1c was measured by an automated ion-exchange
chromatographic method (Bio-Rad Laboratory, Hercules, CA, USA;
with reference range: 5.1–6.4%). Interassay and intra-assay coeffi-
cients of variation for hemoglobin A1c was p3.1% at values below
6.5%. Total cholesterol, TG and HDL-C were measured by
enzymatic methods on a Hitachi 911 automated analyzer (Boeh-
ringer Mannheim, Mannheim, Germany) using reagent kits supplied
by the manufacturer of the analyzer. LDL-C was calculated by the
Friedewald equation.29 The precision performance of these assays
was within the manufacturer’s specifications. Urinary creatinine
(Jaffe’s kinetic method) and albumin (immunoturbidimetry method)
were also measured on the Hitachi 911 analyzer, using reagent
kits supplied by the manufacturer. The interassay precision
coefficients of variation was 12.0 and 2.3% for urinary albumin
concentrations of 8.0 and 68.8 mg/l, respectively. The lowest
detection limit was 3.0 mg/l. Plasma creatinine (Jaffe’s kinetic
method) was measured on a Dimension AR system (Dade Behring,
Deerfield, IL, USA). The laboratory reported that the upper limit of
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normal for plasma creatinine was 106 and 80 mmol/l for male and
female subjects, respectively.
Statistical analysis
The analysis was performed using the Statistical Package for Social
Sciences (version 10.1). TG, SCR and albuminuria were logarith-
mically transformed due to skewed distributions. All data were
expressed as mean7s.d. or median (interquartile range), as
appropriate. Analysis of covariance was used to test the difference
of continuous variables between groups while controlling for
covariates. Logistic regression was used to estimate the relationship
between categories of GFR and the OR with 95% confidence
intervals for macro- and microvascular complications, with the
assumption that the effects of different variables on end points were
constant. Independent variables (age, sex, disease duration, smoking
history (current or ex), family history of diabetes, BMI, waist
circumference, systolic, and diastolic blood pressure, hemoglobin
A1c, FPG, HDL-C, TG, LDL-C, and UAE) were entered in the
regression analysis. A stepwise procedure was used in which
variables were added or removed from the model. A P-value
o0.05 (two-tailed) was considered to be significant.
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